WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investiga - Wikidata - awgldk - TriplyDB

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investiga

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investiga

http://www.wikidata.org/entity/Q34956588

about

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer Albumin-bound paclitaxel in solid tumors: clinical development and future directions Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Genomic profiling in luminal breast cancer Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.nab-Paclitaxel dose and schedule in breast cancer Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.Recent Advances in the Neoadjuvant Treatment of Breast Cancer.Research needs in breast cancer.Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies.HER2-Orientated Therapy in Early and Metastatic Breast Cancer.Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.If Chemotherapy Is Indicated, Give the Optimal Regimen!Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma.

P2860

Q26773012-366CD43E-6A70-4F28-9806-B0D728F58841 Q26785612-DC8957EE-2225-458C-BEEB-B77487541DE1 Q26798674-B516669B-380A-453E-9D0D-F9715E46B11E Q26853619-C372EB34-B67A-40F9-B079-A206D0E52DE6 Q26862681-A95CD5DD-AB82-4C29-8ACC-CBE7326ED688 Q28260063-3C211EBD-0D83-431B-94C2-7A586C97077F Q33587905-6D51D1F8-7E8D-4648-82A3-F12B5B9545CB Q35153559-A2216BC6-A85A-41AB-BE9E-CF0E25268715 Q35734193-0186DFAD-92E2-4B73-A8B5-98FC292735A0 Q36379813-33A1B590-EACD-4F63-8584-D0A0A2C89D9F Q37715554-A6E35F23-FED4-4F55-A38D-318EE384937D Q38671174-461B1C7F-1176-49A7-99BC-BF9BBD57ED4C Q38687392-54EAA34D-3F7D-4A9A-893F-10671742B581 Q38796787-996E4EDC-1EED-4EF2-9722-9232F08B2238 Q39105730-2489FE0D-556C-4F2E-8CB5-1D0F996D31C0 Q39147155-23B2A2EE-1AF4-48B0-BAA2-1CADBFDCCC8C Q39299810-93C9B163-9A72-4D61-8CCE-108AD4258F1C Q39681143-06CE1060-B2CC-4F3A-8B39-A331CB82F257 Q47788774-4A16DCF7-EEEE-4CA7-A29D-BDC7F2A20657 Q54587505-13B33759-4F2F-4E02-851F-E161F1CF3D1A

P2860

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investiga

http://www.wikidata.org/entity/Q34956588

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@ast

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@en

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@nl

type

label

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@ast

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@en

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@nl

prefLabel

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@ast

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@en

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@nl

P1433

Q34956588-5CE861E3-A981-4D7E-A11E-AB774B5A3683

P1476

Q34956588-9142C3F8-F45C-4751-9B43-C7CEA543AA6F

P2093

Q34956588-1947C6DE-2A8B-4C4E-9ED1-73A3FC712691

Q34956588-3FFD7019-E813-4C30-9F36-E16A6FF436E3

Q34956588-52C6393D-350C-41F0-8D15-FAD295BD53B5

Q34956588-9CFB6E88-BCCA-4D9D-B802-2A8D5AD632F7

Q34956588-B8373DFA-8A1D-4E05-A69C-47A0DC296AAC

Q34956588-D883B653-3586-4005-AF8B-6D90DE3B4C73

P2860

Q34956588-0875D9BD-9678-4695-A82B-002ACF8A95B6

Q34956588-26971B02-DB7C-4922-9237-0778EC81CC17

Q34956588-354DD442-4F3D-4CE6-B0F1-BA1DD8BE9BBB

Q34956588-3F30096F-5E34-4BAF-8888-E3B0AA91EAEB

Q34956588-441240F3-012C-4EBD-8D13-40DA785FDFA1

Q34956588-4577617B-641F-4F9E-B1AB-9F19ED3CCF51

Q34956588-471D2C0A-E713-4CE7-A98E-E6D68E62FA3A

Q34956588-4A0FE441-E400-42B7-AC82-9063F9F10BED

Q34956588-5F63D2AF-176E-45FA-A9CF-E92710DB4A36

Q34956588-6F997F47-4C92-4B4E-AD6C-8A2ED6D1061A

P2888

Q34956588-B3CC6629-9C32-48A9-9DEC-20F1F5C551CA

P304

Q34956588-6B8C5942-B058-4A85-843F-C417658EF1B3

P31

Q34956588-2D3B912F-A455-4FCD-8829-A65C3687FE4E

P356

Q34956588-54FA7DED-5783-4CF3-8288-963D3640B4BE

P478

Q34956588-E15D363A-3530-4FF6-ADE7-3446FBDB7963

P50

Q34956588-605F0400-C290-4F1A-A9FC-3AB572783C3B

P577

Q34956588-59B23189-D8A5-49B2-9425-6BF51ABE3094

P5875

Q34956588-8B8E1762-06D2-4A5D-81FE-729BA8BF37DA

P698

Q34956588-7A4663AA-06E9-4A7A-95C5-649E08A92EEE

P932

Q34956588-7E19F2C6-CF4F-4705-A836-71D10239BB74

P356

1745-6215-14-261

P1433

P1476

WSG ADAPT - adjuvant dynamic m ...... blinded, randomized, investiga

@en

P2093

Daniel Hofmann

http://www.w3.org/2001/XMLSchema#string

Oleg Gluz

http://www.w3.org/2001/XMLSchema#string

Peter Staib

http://www.w3.org/2001/XMLSchema#string

Ronald E Kates

http://www.w3.org/2001/XMLSchema#string

Timo Schinkoethe

http://www.w3.org/2001/XMLSchema#string

Ulrike Nitz

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

Quality assessment of HER2 testing by monitoring of positivity rates

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer

Personalized treatment of early-stage breast cancer: present concepts and future directions.

P2888

1745-6215-14-261

P304

261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1745-6215-14-261

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255985013

http://www.w3.org/2001/XMLSchema#string

P698

23958221

http://www.w3.org/2001/XMLSchema#string

P932

3765940

http://www.w3.org/2001/XMLSchema#string